Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
about
Current trends in management of hepatitis B virus reactivation in the biologic therapy eraPrevention of Hepatitis B reactivation in the setting of immunosuppressionHepatitis B and Hepatitis C Reactivation in the Biologic EraManagement of patients with hepatitis B who require immunosuppressive therapyPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveHepatotoxicity of targeted therapy for cancer.Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients.Hepatitis B reactivation in patients receiving targeted therapies.Preventing hepatitis B viral reactivation in patients receiving cancer chemotherapy.Prevention and treatment of hepatitis virus infections in hematopoietic stem cell transplant recipientsLamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation.Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis.
P2860
Q24634879-26DADB88-04F1-4034-B607-D0B1D9ACEBAAQ26747023-44D6C7CB-32EA-4ECF-8E8C-4EDC4B80E53BQ26781993-1F463C22-608F-4E5A-A2A9-B44985510E2BQ26853490-FAFFAF6B-85AD-48AF-9B3B-A8833B1C4E8FQ28070090-E30F9A71-4D66-4CA2-B672-0DA778EC99B6Q28388806-367EB7DA-7F0B-4E19-814D-83E4FE6FCC19Q30250288-9FD8F2DC-6B98-4979-ADA8-83348767DAEDQ35375654-1E199C62-EDB8-42EF-B161-39824752CF02Q35567748-606BB971-4ECA-4ED2-BE99-E98DAB1B6AADQ36980710-7874C4E1-7738-411F-A8EC-6EF51FFD3F05Q37150434-72B25185-E8BA-49D1-B5F6-34E27A0BCFBEQ37942651-7E3C0158-6117-47C8-8916-D2131C926777Q39293427-4A39C5A5-AF9F-4A1D-BE8B-A8F0E58FBC6AQ41790668-9A95E891-6BC1-4FE0-A88C-E5E6E02D3453Q41888846-D1C972FC-CC40-450B-B6EF-10329CE670E4Q42580728-15E5A6B3-1A87-43F3-9C83-7B3F535D95A6Q45324587-D373C11D-4B85-4C23-9AD3-F8982130AFB7Q52653387-032885D3-4958-44AC-B162-5B490C9DF634
P2860
Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Lamivudine prophylaxis and tre ...... transplants with alemtuzumab.
@en
Lamivudine prophylaxis and tre ...... transplants with alemtuzumab.
@nl
type
label
Lamivudine prophylaxis and tre ...... transplants with alemtuzumab.
@en
Lamivudine prophylaxis and tre ...... transplants with alemtuzumab.
@nl
prefLabel
Lamivudine prophylaxis and tre ...... transplants with alemtuzumab.
@en
Lamivudine prophylaxis and tre ...... transplants with alemtuzumab.
@nl
P2093
P50
P356
P1476
Lamivudine prophylaxis and tre ...... l transplants with alemtuzumab
@en
P2093
P304
P356
10.1002/JMV.20705
P577
2006-12-01T00:00:00Z